Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | 10% owner | February 21, 2025 | February 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date February 21, 2025 · Filed February 25, 2025
Jointly reported with Aguilar-Cordova Estuardo
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CADLSEC Table I · non-derivative | IndirectBy LKA 2022 Revocable Trust | 120,861 |
Reported balance
After 2025-02-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-02-21 · Disposition to issuer · Disposed 10,582 · Balance 120,861 F1: Shares of common stock held by spouse LKA 2022 Revocable trust |
| CADLSEC Table I · non-derivative | Direct | 162,929 |
Reported balance
After 2025-02-21 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-02-21 · Disposition to issuer · Disposed 10,583 · Balance 162,929 |
| CADLSEC Table I · non-derivative | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 60,000 F3: Shares of common stock held jointly with spouse |
| CADLSEC Table I · non-derivative | IndirectLaura K. Aguilar 2020 Irrevocable Trust | 2,013,100 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,013,100 F2: Shares of common stock held by spouse irrevocable trust |
| CADLSEC Table I · non-derivative | IndirectBy Estuardo Aguilar-Cordova 2020 Irrevocable Trust | 2,074,942 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,074,942 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock held by spouse LKA 2022 Revocable trust
F2: Shares of common stock held by spouse irrevocable trust
F3: Shares of common stock held jointly with spouse
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2025 Filed Feb 25, 2025 18:35 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 10,583 | $12.02 | $127,207.66 |
DisclosureSEC source: 0001873919-25-000002 · primary_doc.xml · nonDerivative · entry 2 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,929 Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 18:35 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 10,582 | $12.02 | $127,195.64 |
DisclosureSEC source: 0001873919-25-000002 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 120,861 F1 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| February 10, 2025 Filed Feb 13, 2025 11:25 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 31,335 | $8.61 | $269,794.35 |
DisclosureSEC source: 0001873919-25-000001 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 F1 · balance_after: Shares of common stock held jointly with spouse Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 00:37 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 50,000 | $8.85 | $442,500.00 |
DisclosureSEC source: 0001873919-24-000011 · primary_doc.xml · nonDerivative · entry 4 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 131,443 F1 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 00:37 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 50,000 | $8.85 | $442,500.00 |
DisclosureSEC source: 0001873919-24-000011 · primary_doc.xml · nonDerivative · entry 3 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,512 Read SEC document |
| December 26, 2024 Filed Dec 31, 2024 00:37 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 50,000 | $9.01 | $450,500.00 |
DisclosureSEC source: 0001873919-24-000011 · primary_doc.xml · nonDerivative · entry 2 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 181,443 F1 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| December 26, 2024 Filed Dec 31, 2024 00:37 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 50,000 | $9.01 | $450,500.00 |
DisclosureSEC source: 0001873919-24-000011 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,512 Read SEC document |
| December 24, 2024 Filed Dec 26, 2024 18:59 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 50,000 | $8.82 | $441,000.00 |
DisclosureSEC source: 0001873919-24-000010 · primary_doc.xml · nonDerivative · entry 6 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 231,443 F1 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| December 24, 2024 Filed Dec 26, 2024 18:59 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 50,000 | $8.82 | $441,000.00 |
DisclosureSEC source: 0001873919-24-000010 · primary_doc.xml · nonDerivative · entry 5 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,512 Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 18:59 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 50,000 | $8.52 | $426,000.00 |
DisclosureSEC source: 0001873919-24-000010 · primary_doc.xml · nonDerivative · entry 4 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 281,443 F1 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 18:59 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 50,000 | $8.52 | $426,000.00 |
DisclosureSEC source: 0001873919-24-000010 · primary_doc.xml · nonDerivative · entry 3 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,512 Read SEC document |
| December 20, 2024 Filed Dec 26, 2024 18:59 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 100,000 | $9.00 | $900,000.00 |
DisclosureSEC source: 0001873919-24-000010 · primary_doc.xml · nonDerivative · entry 2 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 331,443 F1 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| December 20, 2024 Filed Dec 26, 2024 18:59 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 100,000 | $9.00 | $900,000.00 |
DisclosureSEC source: 0001873919-24-000010 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,512 Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 23:12 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 200,000 | $10.04 | $2,008,000.00 |
DisclosureSEC source: 0001873919-24-000009 · primary_doc.xml · nonDerivative · entry 4 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 431,443 F1 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 23:12 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 200,000 | $10.04 | $2,008,000.00 |
DisclosureSEC source: 0001873919-24-000009 · primary_doc.xml · nonDerivative · entry 3 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,512 Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 23:12 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 200,000 | $8.53 | $1,706,000.00 |
DisclosureSEC source: 0001873919-24-000009 · primary_doc.xml · nonDerivative · entry 2 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 631,443 F1 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 23:12 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 200,000 | $8.53 | $1,706,000.00 |
DisclosureSEC source: 0001873919-24-000009 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 673,512 Read SEC document |
| December 06, 2024 Filed Dec 6, 2024 23:44 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 20,000 | $5.23 | $104,600.00 |
DisclosureSEC source: 0001873919-24-000008 · primary_doc.xml · nonDerivative · entry 3 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,335 F1 · balance_after: Shares of common stock held jointly with spouse Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 23:44 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 20,000 | $4.79 | $95,800.00 |
DisclosureSEC source: 0001873919-24-000008 · primary_doc.xml · nonDerivative · entry 2 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,335 F1 · balance_after: Shares of common stock held jointly with spouse Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 23:44 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 20,000 | $4.46 | $89,200.00 |
DisclosureSEC source: 0001873919-24-000008 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,335 F1 · balance_after: Shares of common stock held jointly with spouse Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 23:24 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 20,000 | $4.97 | $99,400.00 |
DisclosureSEC source: 0001873919-24-000006 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,335 F1 · balance_after: Shares of common stock held jointly with spouse Read SEC document |
| November 08, 2024 Filed Nov 9, 2024 01:58 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 7,500 | $4.92 | $36,900.00 |
DisclosureSEC source: 0001873919-24-000005 · primary_doc.xml · nonDerivative · entry 6 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 831,443 F1 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| November 08, 2024 Filed Nov 9, 2024 01:58 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 7,500 | $4.92 | $36,900.00 |
DisclosureSEC source: 0001873919-24-000005 · primary_doc.xml · nonDerivative · entry 5 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 873,512 Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:58 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 7,500 | $5.19 | $38,925.00 |
DisclosureSEC source: 0001873919-24-000005 · primary_doc.xml · nonDerivative · entry 4 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 838,943 F1 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:58 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 7,500 | $5.19 | $38,925.00 |
DisclosureSEC source: 0001873919-24-000005 · primary_doc.xml · nonDerivative · entry 3 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 881,012 Read SEC document |
| November 06, 2024 Filed Nov 9, 2024 01:58 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 7,500 | $5.33 | $39,975.00 |
DisclosureSEC source: 0001873919-24-000005 · primary_doc.xml · nonDerivative · entry 2 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 846,443 F1 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| November 06, 2024 Filed Nov 9, 2024 01:58 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 7,500 | $5.33 | $39,975.00 |
DisclosureSEC source: 0001873919-24-000005 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 888,512 Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 22:08 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 7,500 | $5.27 | $39,525.00 |
DisclosureSEC source: 0001873919-24-000004 · primary_doc.xml · nonDerivative · entry 6 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 853,943 F2 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 22:08 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 7,500 | $5.27 | $39,525.00 |
DisclosureSEC source: 0001873919-24-000004 · primary_doc.xml · nonDerivative · entry 5 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 896,012 Read SEC document |
| October 31, 2024 Filed Nov 1, 2024 22:08 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 7,500 | $5.30 | $39,750.00 |
DisclosureSEC source: 0001873919-24-000004 · primary_doc.xml · nonDerivative · entry 4 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 861,443 F2 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| October 31, 2024 Filed Nov 1, 2024 22:08 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 7,500 | $5.30 | $39,750.00 |
DisclosureSEC source: 0001873919-24-000004 · primary_doc.xml · nonDerivative · entry 3 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 903,512 Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 22:08 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 6,000 | $5.38 | $32,280.00 |
DisclosureSEC source: 0001873919-24-000004 · primary_doc.xml · nonDerivative · entry 2 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LKA 2022 Revocable Trust Disclosed balance after: 868,943 F2 · ownership.nature: Shares of common stock held by spouse LKA 2022 Revocable trust Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 22:08 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 6,000 | $5.38 | $32,280.00 |
DisclosureSEC source: 0001873919-24-000004 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 911,012 F1 · balance_after: Adjusted by 28,480 shares acquired by Dr. Aguilar-Cordova through option exercise as previously filed on 09/23/2024 Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 22:41 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 11,711 | $5.58 | $65,347.38 |
DisclosureSEC source: 0001873919-24-000003 · primary_doc.xml · nonDerivative · entry 4 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 888,532 Read SEC document |
| October 25, 2024 Filed Oct 28, 2024 22:41 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 1,597 | $5.80 | $9,262.60 |
DisclosureSEC source: 0001873919-24-000003 · primary_doc.xml · nonDerivative · entry 3 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,243 Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 22:41 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 1,194 | $5.72 | $6,829.68 |
DisclosureSEC source: 0001873919-24-000003 · primary_doc.xml · nonDerivative · entry 2 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 901,840 Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 22:41 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Disposition to issuerCADL | 16,427 | $5.53 | $90,841.31 |
DisclosureSEC source: 0001873919-24-000003 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 903,034 Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 21:59 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | SaleCADL | 10,412 | $6.03 | $62,784.36 |
DisclosureSEC source: 0001873919-24-000002 · primary_doc.xml · nonDerivative · entry 3 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 919,461 Read SEC document |
| October 14, 2024 Filed Oct 15, 2024 21:59 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | SaleCADL | 15,000 | $6.02 | $90,300.00 |
DisclosureSEC source: 0001873919-24-000002 · primary_doc.xml · nonDerivative · entry 2 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 929,873 Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:59 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | SaleCADL | 15,000 | $6.05 | $90,750.00 |
DisclosureSEC source: 0001873919-24-000002 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944,873 Read SEC document |
| October 03, 2024 Filed Oct 3, 2024 22:19 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | SaleCADL | 1,800 | $6.85 | $12,330.00 |
DisclosureSEC source: 0001873919-24-000001 · primary_doc.xml · nonDerivative · entry 3 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 959,873 Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 22:19 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | SaleCADL | 26,988 | $6.92 | $186,756.96 |
DisclosureSEC source: 0001873919-24-000001 · primary_doc.xml · nonDerivative · entry 2 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 961,673 Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 22:19 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | SaleCADL | 6,214 | $7.01 | $43,554.55 |
DisclosureSEC source: 0001873919-24-000001 · primary_doc.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · 10% owner Aguilar Laura K. · CIK 0001873915 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 988,661 Read SEC document |
| May 06, 2022 Filed May 10, 2022 22:07 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Exercise / conversionStock Option (Right to Buy) · Derivative | 76,717 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0000899243-22-017477 · doc4.xml · derivative · entry 6 Aguilar Laura K. · CIK 0001873915 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,717 shares Expires 2028-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Includes options that were previously subject to performance vesting criteria. Upon the Reporting Person's termination as an officer of the Issuer, the vesting conditions were waived, and the shares underlying this option became fully vested and exercisable. F4 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| May 06, 2022 Filed May 10, 2022 22:07 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Exercise / conversionStock Option (Right to Buy) · Derivative | 76,717 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0000899243-22-017477 · doc4.xml · derivative · entry 5 Aguilar Laura K. · CIK 0001873915 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,717 shares Expires 2028-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| May 06, 2022 Filed May 10, 2022 22:07 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,901 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0000899243-22-017477 · doc4.xml · derivative · entry 4 Aguilar Laura K. · CIK 0001873915 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,901 shares Expires 2028-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| May 06, 2022 Filed May 10, 2022 22:07 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Tax withholdingCommon Stock | 68,534 | $3.65 | $250,149.10 |
DisclosureSEC source: 0000899243-22-017477 · doc4.xml · nonDerivative · entry 2 Aguilar Laura K. · CIK 0001873915 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,840 F2 · kind: Represents a net exercise of outstanding stock options. These shares were resold to the Issuer as payment of the exercise price, based on the closing price of the Issuer's common stock on May 5, 2022 of $3.65 per share. F1 · balance_after: Includes 32,399 shares of common stock held jointly with spouse. Read SEC document |
| May 06, 2022 Filed May 10, 2022 22:07 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Exercise / conversionCommon Stock | 171,335 | $1.46 | $250,149.10 |
DisclosureSEC source: 0000899243-22-017477 · doc4.xml · nonDerivative · entry 1 Aguilar Laura K. · CIK 0001873915 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 32,399 shares of common stock held jointly with spouse. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:04 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | ConversionSeries B Preferred Stock · Derivative | 137,881 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031088 · doc4.xml · derivative · entry 3 Aguilar Laura K. · CIK 0001873915 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,096 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F2 · ownership.direct: Includes 32,399 shares of common stock held jointly with spouse. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:04 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | ConversionCommon Stock | 56,096 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031088 · doc4.xml · nonDerivative · entry 1 Aguilar Laura K. · CIK 0001873915 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 931,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F2 · balance_after: Includes 32,399 shares of common stock held jointly with spouse. F2 · ownership.direct: Includes 32,399 shares of common stock held jointly with spouse. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.